Public perceptions of naloxone use in the outpatient setting.
| Autor: | Smith JO, Malinowski SS, Ballou JM |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | The mental health clinician [Ment Health Clin] 2019 Jul 01; Vol. 9 (4), pp. 275-279. Date of Electronic Publication: 2019 Jul 01 (Print Publication: 2019). |
| DOI: | 10.9740/mhc.2019.07.275 |
| Abstrakt: | Introduction: Naloxone has become an important component of preventing deaths from opioid overdose. Although studies have confirmed its cost-effectiveness, naloxone is rarely prescribed proactively in case of accidental overdose. The perception still exists that a reversal agent may enable patients with opioid use disorder to continue abusing opioids without fear of death from overdose. This study was designed to determine the general public's knowledge of naloxone and their perceptions about receiving a naloxone prescription with opioid use. Methods: Participants were recruited through Amazon Mechanical Turk (MTurk), where a link directed participants to an electronic survey. Participants were included if they were 18 years of age or greater and currently living in the United States. Participants were paid $0.10 USD via Amazon MTurk upon completing the survey. Results: Four hundred five participants successfully completed the survey, and 61% were aware that there is a medication available to treat opioid overdose. The majority of participants responded positively to the idea of acquiring naloxone. Responses were evenly split for agreeing and disagreeing with the statement "naloxone is only necessary for people who abuse opioids." Although 51% of respondents believed that having naloxone available enables people who abuse opioids, 88% agreed that naloxone is beneficial for people who accidentally overdose on opioids. A majority believed that naloxone should be made available upon request to anyone concerned about opioid overdose. Discussion: Participants were generally aware of the availability of an opioid reversal agent and responded positively to 3 different methods of acquiring naloxone through their prescriber or pharmacist. Competing Interests: Disclosures: The authors have nothing to disclose concerning possible financial or personal relationships with commercial entities that may have a direct or indirect interest in the subject matter of this presentation. This work was presented at The University of Mississippi's Rho Chi Research Day on October 19, 2017; the American Society of Health-System Pharmacists Midyear Clinical Meeting on December 4, 2017; and the Student College of Clinical Pharmacy Research Symposium on January 11, 2018. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|